© 2022 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
Revance Therapeutics announces the FDA has accepted the resubmission for daxibotulinumtoxinA for injection of glabellar lines.
Back in June of 2021, Revance Therapeutics announced the FDA would inmate its pre-approval inspection of the company’s daxibotulinumtoxinA (DAXI, Revance Therapeutics) manufacturing facility.1
Now the botulinum toxin type A injection formulated with a novel peptide excipient has had its Biologics License Application (BLA) resubmission accepted by the FDA for the treatment of moderate to severe glabellar lines.2
The resubmission has been classified as a Class 2 resubmission by the FDA, meaning it is a resubmission that includes any other items, including any item that would warrant presentation to an advisory committee, according to the FDA website.3 The resubmission has a 6-month review period and a reinspection for the company’s manufacturing facitlity. The Prescription Drug User Fee Act (PDUFA) goal date of September 8, 2022.
References: